Sign inJoin waitlistJoin the waitlist

Michael Toboni

Assistant Professor · University of Alabama Hospital

Credentials: · · · · · ·

History

University of Alabama Hospital
Present
University of Alabama Hospital
Present

Complex Family Planning
Washington University/B-JH/SLCH Consortium
2023–2025
Washington University/B-JH/SLCH Consortium
2020–2023
Obstetrics and Gynecology
University of Alabama Hospital
2016–2020
Keck Sch of Med of the Univ of Southern Calif
2011–2015

Research

GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress
Molecular Cancer Research · 2022 · 46 citations
Uterine carcinosarcomas: From pathology to practice
Review · Gynecologic Oncology · 2021 · First of 11 authors · Corresponding · 27 citations
Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 "Lynch-like" mismatch repair gene mutation
Gynecologic Oncology · 2023 · First of 11 authors · Corresponding · 25 citations

Charles Leath
10 papers
Matthew Powell
10 papers
Rebecca Arend
10 papers · 1 as a resident
Premal Thaker
8 papers
KK
Kaitlyn Kincaid
6 papers · 6 as a fellow
Haller Smith
5 papers · 3 as a fellow
Katherine Fuh
5 papers
Teresa Boitano
5 papers · 1 as a fellow
David Mutch
4 papers
Michael Straughn
4 papers
PK
Peter Ketch
4 papers · 4 as a fellow
Andrea Hagemann
3 papers

Clinical trials

Signatera Assessment in Early-Stage Endometrial Cancer
Site PI · Not yet recruiting
Natera, Inc.
2026–2034
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2028
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
Site PI · Recruiting · Phase 1, Phase 2
University of Alabama at Birmingham
2023–2027
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2022–2027